He himself would have cured Donald Trump. Germany is the first country in the European Union to use the experimental treatment based on Covid-19 againstSynthetic Antibody Administered to Former President of the United States Last October. “The government bought 200,000 doses for 400 million euros,” Health Minister Jens Spahn said, representing 2,000 euros per dose.
Patients will receive this therapy free of charge. Two variations of this “monoclonal” antibody-based treatment will be used in university hospitals. Berlin thus obtained its supplies from two American companies, Regeneron for its Casirivimab / Imdevimab and Eli Lilly for its Bamlanivimab.
The two versions of this treatment, which have been approved in the United States but have not yet received the green light from European regulatory authorities, work in a similar way. Unless Regeneron’s version combines two synthetic antibodies and Eli Lilly’s version uses only one. Explanations.
What does this treatment consist of?
These antibodies mimic the functioning of the immune system after infection with the coronavirus. And this by going to block the tip of the virus that allows it to adhere to human cells and penetrate them. These synthetic antibodies “works as a passive vaccine”, Jens Spahn explained.
“These are monoclonal antibodies, in other words, they are antibodies that target a component of the virus, ”Nathan Peiffer-Smadja, infectious disease specialist at the Bichat hospital in Paris, explained in October to the microphone of RTL. “It looks like a little hand that sticks to the virus and prevents it from performing certain functions and, in particular, from entering cells and therefore infecting human cells.”
Effective “during the initial stages”
For Jens Spahn, “the administration of these antibodies during the initial stages of the infection can help high-risk patients to avoid a more serious course.” In fact, this treatment is considered most effective during the initial phase of infection, when the antibodies still have the possibility to control the invader, and not during the second phase of Covid-19, when the danger is no longer the virus itself, but the overreaction of the immune system that attacks the lungs to other organs.